RxDoctor Payments DataLook up a doctor →

Stuart Shafer, MD

Neurology · Vero Beach, FLNPI 1003818816

Payments from drug & device makers

$5,026,436in general payments, 2019–2025

Across 1,732 payments — averaging $2902.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3.7M
  • F. Hoffmann-la Roche AG$254K
  • Roche Products Limited$203K
  • Adamas Pharmaceuticals, Inc.$140K
  • Bristol Myers Squibb$136K
  • Hoffmann-la Roche Limited$127K
  • plus $446K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis111$3,717,757
F. Hoffmann-la Roche AG267$254,449
Roche Products Limited331$203,372
Adamas Pharmaceuticals, Inc.84$140,432
Bristol Myers Squibb21$136,378
Hoffmann-la Roche Limited108$127,272
Alkermes, Inc.64$91,338
Biogen56$81,245
EMD Serono, Inc.103$78,220
Genentech USA, Inc.50$39,157
Genentech, Inc.19$38,508
Sanofi70$30,443
Acadia Pharmaceuticals Inc11$19,511
UCB SA2$14,070
Mallinckrodt Hospital Products Inc.19$10,912
H. Lundbeck A S12$8,291
Mallinckrodt Enterprises LLC9$6,914
Janssen Research & Development, LLC13$6,315
Sunovion Pharmaceuticals Inc.26$5,238
E.r. Squibb & Sons, L.L.C.4$3,346
Boehringer Ingelheim1$2,863
Chugai Pharmaceutical Co., Ltd.4$2,576
Pfizer28$919
AbbVie(2 entities)57$864
Lilly USA, LLC24$568
Teva Pharmaceuticals USA, Inc.19$466
AstraZeneca15$362
Eisai Inc.8$314
UCB, Inc.9$312
Amneal Pharmaceuticals LLC18$308
Lundbeck LLC13$300
Amgen(2 entities)10$280
TG Therapeutics, Inc.10$277
MDD US Operations, LLC13$255
Argenx US, Inc.12$219
Otsuka America Pharmaceutical, Inc.8$163
SK Life Science, Inc.6$147
Merz Pharmaceuticals, LLC5$133
Upsher-smith Laboratories LLC7$129
Johnson & Johnson7$122
Neurocrine Biosciences, Inc.5$110
ANI Pharmaceuticals, Inc.4$104
Acorda Therapeutics, Inc5$103
Supernus Pharmaceuticals, Inc.5$91
Ares Trading SA1$85
Biotronik Inc.1$85
Sumitomo Pharma America, Inc.4$77
Biohaven Pharmaceuticals, Inc.4$76
Biohaven Pharmaceutical Holding Company Ltd.4$73
Takeda Pharmaceuticals U.S.A., Inc.2$68
Tanabe Pharma America, Inc.3$62
Avanir Pharmaceuticals, Inc.4$62
Kyowa Kirin, Inc.3$60
Grifols USA, LLC3$56
Alnylam Pharmaceuticals Inc.2$55
Eli Lilly1$55
C2n Diagnostics, LLC1$44
Arbor Pharmaceuticals, Inc.3$41
Catalyst Pharmaceuticals, Inc.1$38
Microtransponder, Inc.1$36

How this compares

$5,026,436 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$5,397,250
Medicare patients
1,524
Services billed
140,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →